ELISA-Based SpCas9 Residual Protein Detection

ELISA-Based SpCas9 Residual Protein Detection

1. Technical Background

At the end of 2023, the world's first CRISPR-based gene therapy, Casgevy, received approval from both the FDA and the EMA, marking the official entry of gene-editing therapy into a new era of clinical application. With the widespread adoption of gene-editing technologies, the safety risks of Cas9 protein residuals have drawn increasing attention.

Authoritative research has shown that Cas9 protein residuals may induce cytotoxicity and genomic instability, adverse effects mediated through the tumor suppressor protein p53. Virus-mediated overexpression of Cas9 may also trigger innate immune responses in the nervous system, affecting cellular function. Furthermore, the immunogenicity of Cas9 protein may impact the success rate of gene therapy.

The FDA “Guidance on the Integration of Human Genome Editing into Human Gene Therapy Products” requires that the functional activity duration of gene-editing components should be minimized, and that residual gene-editing components should be assessed during product release testing. Technical guidance documents issued by China's Center for Drug Evaluation (CDE) similarly emphasize the need for rigorous detection and control of residuals from editing tools such as Cas9 protein, with the establishment of quantitative detection methods whose detection limits must meet safety requirements.

2. ZhuHai GeneRulor ELISA SpCas9 Residual Protein Detection: Principle and Technical Advantages

2.1 Detection Principle

ZhuHai GeneRulor's ELISA SpCas9 residual protein detection technology employs the Double Antibody Sandwich ELISA (DAS-ELISA) method, which is one of the core technologies currently combining the highest sensitivity and specificity in the field of protein quantification. Its detection principle achieves precise quantification through a "capture antibody – target protein – detection antibody" specific binding system. This technology uses two monoclonal antibodies to recognize different antigenic epitopes of SpCas9, substantially reducing false-positive interference and providing a core guarantee for the high specificity and accuracy of detection results.

Figure 1. Principle of ELISA-based SpCas9 protein detection

2.2 Detection Workflow

(1) Solid-phase stage: enzyme-linked plate wells are pre-coated with anti-Cas9 monoclonal antibody to form a stable solid-phase carrier;

(2) Capture stage: Cas9 nuclease in the sample specifically binds to the solid-phase antibody;

(3) Detection stage: detection antibody is added, forming an "antibody – antigen – antibody" sandwich complex with the bound Cas9;

(4) Signal amplification: HRP-labeled probe is added and binds to the detection antibody for signal amplification;

(5) Color development reaction: HRP catalyzes color development of the substrate; the color intensity is directly proportional to the Cas9 concentration;

(6) Quantitative analysis: absorbance is measured at 450 nm and Cas9 concentration is precisely calculated using a standard curve.

2.3 Technical Advantages

2.4 Operational Advantages

(1) Standardized workflow: 96-well plate design supporting high-throughput batch testing;

(2) Rapid and convenient: the complete detection workflow is completed within 4 hours, significantly improving work efficiency;

(3) Rigorous quality control: every batch of reagents undergoes strict quality control to ensure the stability and consistency of detection results.

2.5 Method Validation: Compliant with Regulatory Standards

Comprehensive method validation is conducted in strict accordance with ICH Q2(R1) guidelines and FDA Bioanalytical Method Validation guidance:

(1) Specificity validation: the dual-antibody recognition system ensures detection specificity with no cross-reactivity;

(2) Accuracy validation: spike-and-recovery validation of reference standards to ensure accurate and reliable detection results;

(3) Precision validation: both within-run repeatability and between-run intermediate precision meet regulatory requirements;

(4) Linearity range validation: good linearity within the 0.25–16 ng/mL detection range;

(5) Limit validation: both the limit of detection (LOD) and limit of quantification (LOQ) meet current regulatory standard requirements.

3. ELISA SpCas9 Residual Protein Detection Application Scenarios (Full-Process R&D Support)

●   Gene-editing cell therapy products: Cas9 residual detection for CAR-T cell therapy, hematopoietic stem cell editing, immune cell modification, and other products;

●   Gene-editing drug R&D: preclinical safety evaluation, process optimization studies, and batch release testing;

●   IND submission support: provision of necessary Cas9 residual data for regulatory submissions of gene-editing products;

●   Quality control applications: establishment of Cas9 residual detection quality standards to support GMP production quality management;

●   Scientific research support: basic research, method validation studies, and safety evaluation research.

4. ELISA SpCas9 Residual Protein Detection Service Content

* Service turnaround: standard workflow 5 business days.

* Expedited service: 3 business days (+20% surcharge).

5. ELISA SpCas9 Residual Protein Detection Sample Requirements

* Notes: (1) All samples must meet the above standards to ensure the accuracy and reliability of detection results. (2) For special sample types, please contact the ZhuHai GeneRulor technical team in advance (Tel: 400-6309596; Order/Technical Support: service@generulor.com).

6. Quality Assurance and Technical Support

ZhuHai GeneRulor has established a comprehensive quality management system. Rigorous quality control standards are implemented for every testing batch to ensure the accuracy and reliability of detection results:

(1) Positive and negative controls to ensure detection accuracy;

(2) Standard curve R² > 0.99 with four-parameter logistic (4PL) fitting;

(3) Detection precision CV < 15%;

(4) Complete testing records and quality assurance system to ensure full traceability;

(5) Provision of detailed experimental reports, including quantitative results, quality control data, and result interpretation.

ZhuHai GeneRulor's professional technical team provides full-process technical consultation and develops customized detection plans based on the client's specific needs, ensuring that detection results comply with regulatory requirements and scientific standards.

Detailed experimental reports and data analysis are provided, including standard curve parameters, sample testing results, and quality control indicator assessment, delivering complete data support for clients' subsequent R&D and regulatory submission work.

7. References

China NMPA CDE Technical Guidance Documents:

[1] National Institutes for Food and Drug Control (NIFDC). Technical Guidelines for Non-Clinical Research and Evaluation of Gene Therapy Products (Trial). November 2021.

[2] National Institutes for Food and Drug Control (NIFDC). Technical Guidelines for Pharmacological Research and Evaluation of In Vivo Gene Therapy Products (Trial). May 2022.

[3] National Institutes for Food and Drug Control (NIFDC). Technical Guidelines for Cell Therapy Products.

[4] Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia, Volume IV.

FDA Regulatory Guidance Documents:

[5] FDA. Gene Therapy QC Testing Guidance.

[6] ICH. Q2(R1) Validation of Analytical Procedures: Text and Methodology.

Scientific Literature:

[7] Zhang X, et al. A Double-Antibody Sandwich ELISA for Sensitive and Specific Detection of Swine Fibrinogen-Like Protein 1. Frontiers in Immunology. 2021;12:670626.

[8] Wang L, et al. Development of an effective one-step double-antigen sandwich ELISA based on p72 to detect antibodies against African swine fever virus. Frontiers in Veterinary Science. 2023;10:1160583.

[9] Zhang X, et al. A Double-Antibody Sandwich ELISA for Sensitive and Specific Detection of Swine Fibrinogen-Like Protein 1. Frontiers in Immunology. 2021;12:670626.